198 related articles for article (PubMed ID: 36465485)
21. KRAS Inhibitor Resistance in
Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
[TBL] [Abstract][Full Text] [Related]
22. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
[TBL] [Abstract][Full Text] [Related]
23.
Tomita Y; Goto Y; Sakata S; Imamura K; Minemura A; Oka K; Hayashi A; Jodai T; Akaike K; Anai M; Hamada S; Iyama S; Saruwatari K; Saeki S; Takahashi M; Ikeda T; Sakagami T
Oncoimmunology; 2022; 11(1):2081010. PubMed ID: 35655708
[TBL] [Abstract][Full Text] [Related]
24. Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
Toral KJ; Wuenschel MA; Black EP
PLoS One; 2021; 16(8):e0256416. PubMed ID: 34437586
[TBL] [Abstract][Full Text] [Related]
25. Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.
Loo K; Smithy JW; Postow MA; Betof Warner A
Front Immunol; 2021; 12():810388. PubMed ID: 35087529
[TBL] [Abstract][Full Text] [Related]
26. CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
[TBL] [Abstract][Full Text] [Related]
27. TCR Repertoire Diversity of Peripheral PD-1
Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance.
Zhou X; Ni Y; Liang X; Lin Y; An B; He X; Zhao X
Front Immunol; 2022; 13():915094. PubMed ID: 36189283
[TBL] [Abstract][Full Text] [Related]
29. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
[TBL] [Abstract][Full Text] [Related]
30. Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression.
Giroux Leprieur E; Hélias-Rodzewicz Z; Takam Kamga P; Costantini A; Julie C; Corjon A; Dumenil C; Dumoulin J; Giraud V; Labrune S; Garinet S; Chinet T; Emile JF
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581058
[TBL] [Abstract][Full Text] [Related]
31. Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer.
Petty RD; Kerr KM; Murray GI; Nicolson MC; Rooney PH; Bissett D; Collie-Duguid ES
J Clin Oncol; 2006 Apr; 24(11):1729-44. PubMed ID: 16549823
[TBL] [Abstract][Full Text] [Related]
32.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer.
Sanber K; Rosner S; Forde PM; Marrone KA
BioDrugs; 2023 Nov; 37(6):775-791. PubMed ID: 37603233
[TBL] [Abstract][Full Text] [Related]
34. IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137
Ugolini A; Zizzari IG; Ceccarelli F; Botticelli A; Colasanti T; Strigari L; Rughetti A; Rahimi H; Conti F; Valesini G; Marchetti P; Nuti M
EBioMedicine; 2020 Dec; 62():103098. PubMed ID: 33166793
[TBL] [Abstract][Full Text] [Related]
35. Identification and Validation of
Li Z; Wang X; Yang Y; Shi F; Zhang W; Wang Q; Wang S
Cells; 2022 Nov; 11(23):. PubMed ID: 36497098
[TBL] [Abstract][Full Text] [Related]
36. CD8
Duchemann B; Naigeon M; Auclin E; Ferrara R; Cassard L; Jouniaux JM; Boselli L; Grivel J; Desnoyer A; Danlos FX; Mezquita L; Caramella C; Marabelle A; Besse B; Chaput N
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131864
[TBL] [Abstract][Full Text] [Related]
37. PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.
Dong Y; Zhao L; Duan J; Bai H; Chen D; Li S; Yu Y; Xiao M; Zhang Q; Duan Q; Sun T; Qi C; Wang J; Wang Z
Cell Prolif; 2022 Sep; 55(9):e13283. PubMed ID: 35811392
[TBL] [Abstract][Full Text] [Related]
38. Identification of Deleterious
Zhang K; Hong X; Song Z; Xu Y; Li C; Wang G; Zhang Y; Zhao X; Zhao Z; Zhao J; Huang M; Huang D; Qi C; Gao C; Cai S; Gu F; Hu Y; Xu C; Wang W; Lou Z; Zhang Y; Liu L
Clin Cancer Res; 2020 Jul; 26(14):3649-3661. PubMed ID: 32241817
[TBL] [Abstract][Full Text] [Related]
39. DNA repair and immune checkpoint blockade response.
Guo JA; Alshalalfa M; Kim DY; Hoffman HI; Shiau C; Su J; Hwang WL; Mahal BA
Cancer Genet; 2022 Jun; 264-265():1-4. PubMed ID: 35245846
[TBL] [Abstract][Full Text] [Related]
40. KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer.
Zhou X; Wang N; Zhang Y; Yu H; Wu Q
Invest New Drugs; 2022 Feb; 40(1):43-57. PubMed ID: 34499335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
